Novartis, Medicines for Malaria Say Treatment for Babies Shows Efficacy
By Adria Calatayud
Novartis and Medicines for Malaria Venture said a new treatment for babies with malaria who weigh less than 5 kilograms showed positive efficacy and safety effects in a clinical study.
Swiss pharmaceutical company Novartis and nonprofit organization Medicines for Malaria Venture said Wednesday that they submitted data from their phase 2 and 3 trial for regulatory review.
The study analyzed a new formulation of Novartis's Coartem drug to account for metabolic differences in the smallest babies, they said.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
April 24, 2024 01:31 ET (05:31 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk